Physician profile
John S Gardner
NPI 1184883852
$9,621.63
in general payments reported to CMS, 2019-2025
42 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $188 · 2021: $774 · 2022: $1,605 · 2023: $1,586 · 2024: $2,149 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477 · Travel and Lodging: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,476.50 |
| Travel and Lodging | $1,222.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,697.41 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,585.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,272.35 | 2019-2025 | |
| Medtronic, INC. | $1,116.06 | 2021-2025 | Symplicity G3, Onyx Frontier, Resolute Onyx |
| Edwards Lifesciences Corporation | $729.42 | 2023-2025 | Evoque, Pascal |
| Merck Sharp & Dohme LLC | $338.54 | 2022-2025 | Verquvo, Capvaxive, Winrevair |
| Pfizer INC. | $309.59 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $300.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $223.26 | 2019-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $195.55 | 2020-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $158.25 | 2025 | |
| Abiomed | $157.68 | 2022-2023 | Impella |
| Chiesi USA, INC. | $128.59 | 2019-2025 | Cleviprex, Kengreal |
| Stryker Corporation | $128.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.87 | 2019-2024 | Jardiance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $105.70 | 2025 | Attruby |
| Lundbeck LLC | $80.78 | 2019-2020 | |
| Philips North America LLC | $74.58 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Cardiva Medical, INC. | $70.73 | 2024-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Terumo Medical Corporation | $68.45 | 2023-2025 | Angio-Seal, Glidewire |
| Daiichi Sankyo INC. | $63.67 | 2024-2025 | Injectafer |
| Boston Scientific Corporation | $63.14 | 2024-2025 | Watchman Flx, Eluvia |
| Impulse Dynamics (USA) INC. | $61.78 | 2022-2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $58.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.75 | 2019-2023 | |
| Amarin Pharma, INC. | $53.54 | 2019 | |
| Alnylam Pharmaceuticals INC. | $50.24 | 2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.65 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $45.22 | 2025 | Wegovy |
| Medtronic Vascular, INC. | $41.40 | 2019-2020 | |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Shockwave Medical, INC | $22.31 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Angiodynamics, INC. | $19.69 | 2025 | Auryon Laser System 100-120 Vac |
| Esperion Therapeutics, INC. | $19.44 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $18.90 | 2022 | |
| Akcea Therapeutics, INC. | $18.74 | 2019 | |
| Bard Peripheral Vascular, INC. | $18.73 | 2019 | |
| Tactile Systems Technology INC | $18.02 | 2019 | |
| Scpharmaceuticals INC. | $16.19 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $13.90 | 2019 | |
| Cvrx, INC. | $8.86 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $8.28 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.